Androgen-deprivation therapy, a mainstay in the treatment of locally advanced and metastatic prostate cancer, is associated with significant bone loss and related complications, such as fracture. Bisphosphonates, osteoclast inhibitors, are effective in preventing skeletal-related events in patients with metastatic prostate cancer and also in preventing bone loss in patients with locally advanced disease. Understanding the management of bone health, including identifying patients at risk, the most appropriate therapy, and monitoring and managing side effects, is critical. This review provides the most recent bone health risk factor and bisphosphonate data available for prostate cancer patients.
Introduction
The use of androgen-deprivation therapy (ADT) in prostate cancer patients causes significant bone lossoften leading to osteoporosis and an increased risk of fracture-that may be compounded by the presence of bone metastases. Bone metastases disrupt the normal bone remodeling process by increasing bone resorption, which weakens the bone matrix and increases the risk of other bone complications, such as spinal cord compression, impaired mobility and bone pain. 1 Bone mineral density (BMD) is reduced by 0.6-5.3% annually in patients with locally advanced disease and 2.3-6.6% in patients with metastatic disease receiving ADT, exceeding by 5-to 10-fold the normal bone loss rates of similarly aged otherwise healthy men and prostate cancer patients not receiving ADT. [2] [3] [4] [5] [6] [7] [8] Consequently, patients receiving ADT are 7-45% more likely to experience a fracture than patients not receiving ADT. [9] [10] [11] Bisphosphonates have been shown to prevent bone loss and related complications in patients with locally advanced and metastatic prostate cancer and should be considered as part of cancer treatment when ADT is initiated in these patients. Urologists are playing an increasingly active role in the treatment and care of prostate cancer patients who are being diagnosed earlier and living longer because of recent therapeutic advances.
As a result, monitoring and managing long-term adverse effects associated with cancer therapies are becoming increasingly important. This article aims to provide the most recent data on the prevention and treatment of bone loss and related complications with bisphosphonates in prostate cancer patients.
Risk factors
Although several studies have evaluated risk factors for bone loss and fractures in prostate cancer patients receiving ADT, the risk factors deemed significant by investigators have varied among studies (Table 1) . 1, 10, [12] [13] [14] [15] [16] The three risk factors that have been reliably identified in patients with locally advanced disease are older age, low body mass index and a long duration of ADT. In metastatic prostate cancer, the only reliable risk factor is elevated levels of deoxypyridinoline.
1 Lifestyle-factor modifications, such as reducing alcohol intake, quitting smoking, participating in a regular weight-bearing or resistance exercise program (20-45 min per session, 2-4 times per week) and taking daily calcium and vitamin D supplements (500-1500 mg and 400-800 IU, respectively) have all been shown to help reduce bone loss in otherwise healthy men and women at risk of osteoporosis. 8, 17 Therefore, prostate cancer patients with these risk factors should receive counseling about appropriate lifestyle-factor modifications.
In patients with metastatic disease, risk factors for bone loss and fracture seem to correlate with extent of disease (Table 1) ; however, all patients with bone metastases are at risk of bone loss and other bone complications and should receive counseling about lifestyle-factor modifications that may decrease their risk of bone loss.
Effect of bisphosphonates on preventing or treating bone complications
Bisphosphonates, synthetic analogs of the endogenous pyrophosphate molecule, inhibit osteoclast-mediated bone destruction in patients receiving ADT and/or with metastatic disease. 4, 6, 18 These drugs selectively adsorb to mineral surfaces on bone that are surrounded by osteoclasts. 18 The bisphosphonates are then released from the bone surface, where they are internalized by and disrupt the bone-resorbing action of osteoclasts. 18 At least two types of bisphosphonates exist: non-nitrogen-containing bisphosphonates (clodronate, etidronate) and the more potent nitrogen-containing bisphosphonates (alendronate, ibandronate, pamidronate, risedronate, zoledronic acid). 18 Both types of bisphosphonates have been evaluated in prostate cancer patients at risk of bone complications. Pamidronate has been shown to maintain BMD during ADT, whereas alendronate and zoledronic acid have been shown to increase BMD during ADT. [2] [3] [4] [5] [6] [7] 19 Zoledronic acid has also been shown to prevent metastatic disease-induced bone complications (for example, fractures, spinal cord compression) in patients with hormone-refractory disease. 20, 21 At this time, no bisphosphonate is indicated for the prevention or treatment of ADT-induced bone loss; however, alendronate is indicated for treatment of men with osteoporosis. 8 Zoledronic acid is the only bisphosphonate indicated for the treatment of bone metastases from solid tumors, such as prostate cancer. 22 Recently, the results of several studies evaluating bisphosphonates for the prevention and treatment of bone loss in earlystage prostate cancer have been presented at national meetings or published (Table 2) , and several others are ongoing. [2] [3] [4] 6, 7 Additionally, ongoing studies are evaluating the use of bisphosphonates for the prevention of bone metastases in patients with advanced disease.
Locally advanced disease
The oral bisphosphonate alendronate is a well-established and effective therapy for osteoporosis in otherwise healthy men. The administration of alendronate 10 mg once daily has been shown to increase BMD of the lumbar spine and total hip (the two most common sites of bone loss), prevent further reductions in height and reduce the incidence of fracture. 23, 24 Recently, the results of a randomized clinical trial evaluating the use of alendronate (70 mg per week) in prostate cancer patients with locally advanced disease have been published. 19 Greenspan et al. 19 showed that weekly alendronate effectively prevented bone loss in men with prostate cancer receiving ADT, with BMD increases of 0.7-3.7% occurring depending on the site measured (Table 2) . Additionally, levels of bone metabolism markers (for example, N-telopeptide) significantly decreased with alendronate when compared with placebo.
The intravenous (i.v.) bisphosphonates pamidronate and zoledronic acid have both been evaluated for the prevention of bone loss in these patients. Pamidronate (60 mg, i.v., q (every) 12 weeks) effectively reduced levels of bone metabolism markers and prevented bone loss compared with placebo, suggesting that pamidronate slows or halts the bone-loss process ( Table 2) . 5 Similar results have been observed with zoledronic acid (4 mg, i.v., q 3 months) when the drug is initiated concurrently with or during the first year of ADT.
2-4,6,7 Unlike pamidronate, zoledronic acid not only maintained but increased BMD beyond baseline levels at all sites measured (0.7-5.6%), providing a more protective effect against the continuous bone loss associated with ADT ( Figure 1 ; Table 2) . [2] [3] [4] 6, 7 Results of a recent study suggest that a one-time zoledronic acid dose (4 mg, i.v.) produces similar increases in lumbar spine BMD to those reported with every 3-month administration ( Figure 1 ; Table 2 ). 3 Additional studies are needed to determine the optimal zoledronic acid regimen in this high-risk patient population.
Patients with normal and low baseline T scores receiving zoledronic acid experience increases in BMD. 4, 7 In a study by Smith et al., 4 patients with normal BMD (T score XÀ1) experienced a 6.1% increase in lumbar spine BMD by month 12 with concurrent initiation of zoledronic acid and ADT, whereas patients with a low BMD (T score oÀ1 and 4À3) experienced a 5.7% increase. Israeli et al. 7 observed similar increases in lumbar spine BMD in patients with normal (T score XÀ1) and low (T score oÀ1 and XÀ2) baseline BMD in patients who had received p12 months of ADT before beginning zoledronic acid therapy (4.4 vs 5.8%, respectively). Therefore, the prophylactic use of bisphosphonates in prostate cancer patients with locally advanced disease, regardless of baseline BMD values, seems rational and appropriate. Routine BMD measurements (that is, every 12 months) during therapy are recommended to ensure that the patient is experiencing BMD stabilization or increases as a result of bisphosphonate therapy. 25 
Metastatic disease
The results of studies evaluating the non-nitrogencontaining bisphosphonates clodronate and etidronate for the prevention of bone complications, including bone pain, in prostate cancer patients with metastatic disease showed transient decreases in pain and analgesic use; however, these bisphosphonates failed to provide significant overall clinical benefit. 8, 18 Similarly, in a combined analysis of two multicenter, double-blind, placebo-controlled trials, pamidronate, a more potent BMD measured by dual-energy X-ray absorptiometry unless otherwise specified. P-values provide a comparison between treatment groups at end of study unless otherwise specified. d Interim analysis of 12-month data; study is planned to continue for 24 months. e Duration of prior ADT at study entry not reported. Abbreviations: ADT, androgen deprivation therapy; BMD, bone mineral density; i.v., intravenous.
Bone health in prostate cancer patients TJ Polascik i.v. bisphosphonate, failed to significantly reduce bone pain or the incidence of skeletal-related events (SREs; see Table 3 for definition of SREs). 18, 26 In contrast, intermittent administration of zoledronic acid for up to 24 months produced significant and sustained reductions in bone pain and related complications. 20, 21 In a randomized study evaluating men with hormone-refractory metastatic prostate cancer, zoledronic acid (4 mg, i.v., q 3 weeks) significantly reduced the percentage of patients experiencing SREs compared with placebo at 15 and 24 months (Figure 2 ; Po0.05) and the median time to the first SRE by more than 5 months (488 vs 321 days; P ¼ 0.009). 20, 21 Furthermore, the overall risk of developing an SRE was reduced by 36% with zoledronic acid (risk ratio, 0.64; 95% confidence interval, 0.485-0.845; P ¼ 0.002). 21 The results of a stratified analysis comparing the incidence of SREs during the study in patients with and without an SRE before study entry showed that patients with an SRE before study entry experienced a higher incidence of SREs during the study than those without an SRE at study entry. 21 Therefore, continuing zoledronic acid therapy in a patient who has experienced a fracture is likely to reduce the risk or time to the development of subsequent fractures or other SREs.
Although all patients reported increasing bone pain throughout the study, patients receiving zoledronic acid reported consistently lower increases in pain scores (Po0.05 by 21 months) throughout therapy. 21 Additionally, in patients with baseline pain, patients receiving zoledronic acid experienced significant decreases in pain by month 3 compared to patients receiving placebo, who experienced increases in pain (P ¼ 0.021). 27 These results demonstrate achievement of durable reductions in bone pain with the administration of zoledronic acid in prostate cancer patients with metastatic disease. 21, 27 Zoledronic acid is often and can be used in combination with other pain therapies, including opioids, radiation therapy, chemotherapy and surgery to bone; nonsteroidal anti-inflammatories should be avoided because of the risk of renal dysfunction. 20, 28 However, the use of zoledronic acid generally reduces the requirement of additional therapies to treat pain over time. 20, 21 Therefore, when using analgesics to treat acute pain, pain scores should be routinely monitored because the amount of analgesics required to treat pain may decrease after the full analgesic effect of zoledronic acid occurs.
Based on the inclusion criteria from the pivotal phase III study, zoledronic acid was approved for the treatment of bone metastases in prostate cancer patients whose disease had progressed after treatment with at least one type of ADT; it has been shown to reduce metastasisrelated bone complications in this population. [20] [21] [22] The results of an open-label study evaluating zoledronic acid in prostate cancer patients with hormone-sensitive metastatic disease showed that zoledronic acid effectively increased BMD and reduced levels of bone metabolism markers in these patients. 29 Furthermore, only 11.9% of these patients developed an SRE, suggesting that zoledronic acid prevents bone complications in patients with both hormone-sensitive and -resistant metastatic disease. 29 The National Comprehensive Cancer Network Guidelines on Prostate Cancer state that early intervention with bisphosphonates in all prostate cancer patients receiving ADT may improve quality of life and prevent morbidity associated with ADT-or metastatic disease-induced bone loss.
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Safety
Oral alendronate is generally well tolerated, although improper administration can lead to esophagitis.
31
Esophagitis can usually be prevented if the patient follows guidelines for proper administration (Table 4) . However, patients with a history of upper gastrointestinal tract disorders should not receive alendronate. Zoledronic acid is generally safe and well tolerated. Transient, mild-to-moderate flulike symptoms, including fever, myalgia, increased bone pain, nausea and vomiting, have been reported primarily after the first infusion, but are generally relieved with analgesics, oral fluids and antiemetics (Table 4) . 28 Zoledronic acid has been associated with renal dysfunction; however, when administered over 15 min instead of 5 min, renal dysfunction was significantly less common. In the pivotal study evaluating zoledronic acid (4 mg, i.v. over 15 min, q 3 weeks) in patients with metastatic disease, serum creatinine (SCr) levels increased in 15.2% of patients compared to 11.5% of patients receiving placebo. 20 In the studies evaluating zoledronic acid (4 mg, i.v., q 3 months) in locally advanced disease, SCr levels significantly increased in o1% of patients.
2-4,6,7 These study results suggest that renal impairment may be more common in patients with shorter infusion times (that is, 5 vs 15 min) and dosage intervals (that is, q 3 weeks vs q 3 months). Nonetheless, serial SCr levels should be monitored and therapy temporarily withheld in patients with significant SCr-level increases (Table 4) . 28 Table 4 provides additional recommendations for preventing and managing renal dysfunction.
Recently, osteonecrosis of the jaw (ONJ), which can occur spontaneously or after an invasive dental procedure, has been reported primarily in patients receiving i.v. bisphosphonates for advanced malignancies. 32 ONJ has also been reported in a small number of patients receiving oral bisphosphonates for noncancer indications. 32 However, no reports of ONJ were reported in Bone health in prostate cancer patients TJ Polascik clinical trials evaluating alendronate or zoledronic acid in prostate cancer patients. [2] [3] [4] 6, 7, 20, 21 Although the time to onset of ONJ is unknown, a retrospective review reported that patients with ONJ had a longer duration of disease, follow-up, i.v. bisphosphonate therapy, and higher cumulative dose of i.v. bisphosphonate compared with cancer patients without ONJ. 33 The underlying mechanism and incidence of and risk factors for ONJ have yet to be fully elucidated, but patients undergoing invasive dental procedures during bisphosphonate therapy seem to be at higher risk. 32 Other risk factors for ONJ are listed in Table 5 . 32 Prevention of ONJ is the goal, and good communication among the patient, dental specialist and urologist is essential for attaining this goal. Table 4 provides recommendations for preventing and treating ONJ. Routine discontinuation of bisphosphonate therapy when signs or symptoms of ONJ occur is not currently recommended because evidence showing improved healing of ONJ after bisphosphonate discontinuation does not exist; however, the potential benefits and risks of continuing therapy should be discussed among the urologist, dental specialist and patient. 32 The long-term safety of bisphosphonates has not been formally evaluated in prostate cancer patients. In patients with metastatic disease, 24 months of zoledronic acid therapy was well tolerated and continued zoledronic acid therapy beyond 24 months should be considered as long as a perceived patient benefit exists. 21 In patients with locally advanced disease, studies evaluating alendronate and zoledronic acid administration for longer than 12 months are ongoing but currently have not been reported.
Conclusions
Maintaining bone health has recently emerged as a critical issue in the treatment of prostate cancer patients with locally advanced or metastatic disease. All patients receiving long-term ADT or with bone metastases are at high risk of developing bone complications, including bone loss and fractures in patients with locally advanced disease and SREs in patients with metastatic disease. Bisphosphonates have been shown to prevent bone complications in these patients and are well tolerated. Urologists can play a key role in managing the bone health of prostate cancer patients by identifying patients at risk, prescribing and administering appropriate therapy, and monitoring for and managing adverse effects. 
